Table 5. Treatment Effects on 30-day Mortality in Patients with SFTS.
| Variables | Univariate Analysis | Multivariate Analysisa | ||||
|---|---|---|---|---|---|---|
| HR | (95% CI) | P Value | aHR | (95% CI) | P Value | |
| Prior antibiotic treatment | 1.55 | (0.76–3.16) | .234 | - | ||
| Ribavirin | 1.61 | (0.75–3.45) | .217 | - | ||
| Steroids | 4.57 | (1.96–10.66) | < .001 | 3.45 | (1.31–9.11) | .012 |
| IVIG | 1.61 | (0.74–3.51) | .235 | - | ||
| Plasmapheresis | 2.19 | (1.03–4.68) | .043 | - | ||
Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; HR, hazard ratio; IVIG, intravenous immunoglobulin
a The variables included in the multivariate model were prior antibiotic treatment, ribavirin, steroids, IVIG, plasmapheresis, and adjusted variables such as age, sex, initial APACHE II score, and symptom onset to admission within 7 days.